Business
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for
About this update from Xencor, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell activation was enhanced in combination with a CD3 T cell engager. The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.\n\n\nT cells in the tumor microenvironment require engagement of both their T cell receptor (TCR) and their co-stimulatory receptors, like CD28, to achieve full activation. The CD28 signal is diminished in cancer because tumor cells do not typically express CD28 ligands (i.e., CD80 and CD86), which leads to potentially compromised activity of CD3 T cell engagers or anti-PD1 checkpoint inhibitors.\n\n\nXencor has developed a modular XmAb® bispecific antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement. Xencor’s XmAb bispecific Fc domain serves as a scaffold for a non-superagonist anti-CD28 binding domain and any tumor-associated antigen of interest. Xencor’s Xtend™ Fc technology further enhances circulating half-life of the antibody.\n\n\n“Xencor has rapidly generated multiple CD28 co-stimulatory bispecific antibodies with potential broad applicability across a range of solid tumors, and each of these programs has demonstrated compelling activity,” said John Desjarlais, Ph.D., executive vice president and chief scientific officer at Xencor. “We are leveraging the plug-and-play nature of our XmAb bispecific antibody platforms to generate and explore additional CD28 drug candidates against a broader universe of solid tumor targets.”\n\n\nThe poster will be archived under \"Events & Presentations\" in the Investors section of the Company's website located at www.xencor.com.\n\n\nAbout XmAb808 (B7-H3 x CD28)\n\n\nXencor is conducting a Phase 1 study of XmAb808 in patients with advanced solid tumors. XmAb808 is...